EGFR and non-small cell lung carcinoma: First-generation EGFR-TKIs (gefitinib, erlotinib) have been widely used, with gefitinib approved by the FDA as first-line treatment for advanced NSCLC patients with activating EGFR mutations (Kazandjian et al., 2016).